New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country.
The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and Oxford University.
In in its application to the the Drug Controller General of India (DCGI), SII cited “unmet medical needs due to the pandemic and in the interest of the public at large” as the reason for seeking emergency authorisation of the vaccine emergency use approval.
Earlier, Pfizer India became the first pharmaceutical firm to seek emergency use authorisation for its COVID-19 vaccine candidate in the country.
Bhubaneswar: The Odisha government is committed towards achieving 7.5 GW of solar energy by 2030…
Mumbai: Dharma Productions new social media post has left netizens speculating about a sequel to…
Bhubaneswar: Asma al-Assad, wife of ousted Syrian president Bashar al-Assad, has reportedly filed for divorce…
Cuttack: The second campus of SCB Medical College and Hospital in Cuttack would be completed…
Cuttack: Armed miscreants threatening businessmen and looting them at gunpoint appeared to have become a…
Hyderabad: A day after vandalism at Allu Arjun’s Jubilee Hill residence, the state police on…
This website uses cookies.